Therapeutic plasmid DNA versus siRNA delivery: Common and different tasks for synthetic carriers

Gene therapy offers great opportunities for the treatment of severe diseases including cancer. In recent years the design of synthetic carriers for nucleic acid delivery has become a research field of increasing interest. Studies on the delivery of plasmid DNA (pDNA) have brought up a variety of gen...

Full description

Saved in:
Bibliographic Details
Published in:Journal of controlled release 2012-07, Vol.161 (2), p.554-565
Main Authors: Scholz, Claudia, Wagner, Ernst
Format: Article
Language:English
Subjects:
Cancer
Carrier uptake
Controlled release
DNA
DNA - administration & dosage
DNA - chemistry
DNA delivery
Gene silencing
Gene therapy
Gene transfer
Gene Transfer Techniques
genes
Humans
Lipidic carriers
mechanism of action
Nanoparticles - administration & dosage
nucleic acids
Plasmids
Plasmids - administration & dosage
Plasmids - genetics
Polyplexes
RNA, Small Interfering - administration & dosage
RNA, Small Interfering - chemistry
siRNA
siRNA conjugates
siRNA delivery
small interfering RNA
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gene therapy offers great opportunities for the treatment of severe diseases including cancer. In recent years the design of synthetic carriers for nucleic acid delivery has become a research field of increasing interest. Studies on the delivery of plasmid DNA (pDNA) have brought up a variety of gene delivery vehicles. The more recently emerged gene silencing strategy by the intracellular delivery of small interfering RNA (siRNA) takes benefit from existing expertise in pDNA transfer. Despite common properties however, delivery of siRNA also faces distinct challenges due to apparent differences in size, stability of the formed nucleic acid complexes, the location and mechanism of action. This review emphasizes the common aspects and main differences between pDNA and siRNA delivery, taking into consideration a wide spectrum of polymer-based, lipidic and peptide carriers. Challenges and opportunities which result from these differences as well as the recent progress made in the optimization of carrier design are presented. [Display omitted]
ISSN:0168-3659
1873-4995
DOI:10.1016/j.jconrel.2011.11.014